Mylan Signals $5.3B Abbott Inversion On Track After Tweaks
Mylan Inc. and Abbott Laboratories said Wednesday that new limitations imposed by the Obama administration on tax-motivated M&A wouldn't derail their planned $5.3 billion inversion deal, though they did modify the...To view the full article, register now.
Already a subscriber? Click here to view full article